Novo Nordisk’s diabetes drug Ozempic reduces the risk of kidney failure and death in patients who have both Type 2 diabetes and chronic kidney disease
Patients taking Ozempic had a 24% lower risk of severe kidney outcomes and death from cardiovascular or kidney causes
People taking Ozempic also had a slower rate of kidney-function decline and had an 18% lower risk of heart attack and other major cardiovascular events, the study found.
The results show “a profound clinical impact saving kidneys, hearts and lives, for patients with Type 2 diabetes and chronic kidney disease
Chronic kidney disease, which raises the risk of heart disease, stroke and other health problems, affects about 14% of U.S. adults
Current kidney-disease treatments can help protect the kidneys and cut cardiovascular risks,
The new study data showing improvements in both cardiovascular and kidney outcomes make “a compelling case” for expansion of Ozempic’s label to treat this group of patients
The data are also “a positive for the broader use of GLP-1 medications for improving patient risk” from chronic kidney disease, Seigerman wrote.